LINC01595: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC01595

NCBI ID: G102725176

LINC01595

Other Name(s): long intergenic non-protein coding RNA 1595 | LINC01595 variant X1 | Long intergenic non-protein coding RNA 1595, transcript variant X1

LINC01595: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

LINC01595 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various studies as a potential drug target or biomarker. It is a non-coding RNA molecule that is expressed in a variety of tissues and cells, including brain, heart, and cancer cells. LINC01595 has been shown to play a role in several cellular processes, including cell signaling, cell division, and tissue development.

Drug Target Potential

LINC01595 has been identified as a potential drug target due to its unique structure and its involvement in several cellular processes that are associated with human diseases. One of the key reasons for its potential as a drug target is its unique structure, which allows it to interact with a variety of different proteins. LINC01595 has been shown to interact with several protein molecules, including the protein known as FAK.

FAK is a protein that is involved in several cellular processes, including cell signaling, cell division, and tissue development. It is a protein that has been linked to several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. LINC01595 has been shown to play a role in the regulation of FAK activity, which suggests that it may be a useful target for drugs that are designed to inhibit FAK activity.

Another potential reason for LINC01595's potential as a drug target is its involvement in several diseases that are characterized by the over-expression of FAK. For example, LINC01595 has been shown to be highly expressed in several neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. The over-expression of FAK in these diseases is thought to contribute to the development and progression of these diseases. LINC01595 may be a useful target for drugs that are designed to reduce the expression of FAK.

Biomarker Potential

In addition to its potential as a drug target, LINC01595 may also be a useful biomarker for several diseases. For example, LINC01595 has been shown to be highly expressed in several types of cancer, including breast cancer and lung cancer. The over-expression of LINC01595 in these cancers is thought to contribute to their development and progression. LINC01595 may be a useful biomarker for these diseases, as it can be used as a target for drugs that are designed to inhibit the expression of LINC01595 in cancer cells.

Another potential use for LINC01595 as a biomarker is its involvement in the regulation of cellular processes that are associated with several diseases. For example, LINC01595 has been shown to play a role in the regulation of cell division, which is thought to contribute to the development and progression of several diseases, including cancer. LINC01595 may be a useful biomarker for these diseases, as it can be used as a target for drugs that are designed to inhibit its activity.

Conclusion

LINC01595 is a long intergenic non-protein-coding RNA that has been identified in several studies as a potential drug target or biomarker. Its unique structure and its involvement in several cellular processes that are associated with human diseases make it a promising candidate for both drug targeting and biomarker development. Further research is needed to fully understand the role of LINC01595 in these processes and to determine its potential as a drug target or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1595

The "LINC01595 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01595 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets